Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Reistone Starts Global Trial of JAK1 Inhibitor for Atopic Dermatitis

publication date: May 14, 2021

Shanghai Reistone Biopharma has started a global Phase III clinical trial of its Janus kinase type 1 (JAK1) inhibitor in patients with Atopic Dermatitis. SHR0302 is a novel, oral JAK1 inhibitor that Reistone expects will offer an improved safety and efficacy profile compared to pan-JAK inhibitors by avoiding the hematological side effects of JAK2 inhibition. The company, which focuses on bringing China-sourced novel products for autoimmune/inflammatory conditions to global markets, in-licensed global rights to the candidate in autoimmune diseases from Jiangsu Hengrui Medicine. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital